First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors

NCT03758001 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: IBI101
DRUG: IBI101
DRUG: Sintilimab

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.